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We are all aware of methicillin-resistant Staphylo-
coccus aureus (MRSA) as a predominant and
dangerous nosocomial pathogen. We also recog-
nise the increased prevalence of antimicrobial
resistance among Gram-positive and Gram-neg-
ative pathogens worldwide, including emerging
resistance against vancomycin and other drug
classes such as the cephalosporins, macrolides,
and quinolones. In the USA, an increasing num-
ber of patients admitted to hospital are already
colonised with resistant pathogens, including
methicillin-sensitive S. aureus and MRSA. Increas-
ing problems with resistance will complicate
initial antimicrobial treatment, especially with
infections due to MRSA.
The limitations of current antimicrobial agents
are narrow spectrum of activity, bacteriostatic
rather than bactericidal activity, rapid develop-
ment of resistance even with newly licensed
antibiotics, and tolerability problems, especially
during long-term treatment. In addition, the
pharmacokinetic–pharmacodynamic properties
of vancomycin, for instance, which has been
considered a standard therapy, are not optimal.
In this environment of increasing antimicrobial
resistance, there is an urgent need for new
antimicrobial agents with activity against resist-
ant pathogens.
What, then, is the rationale for developing new
cephalosporin antibiotics with activity against
MRSA? Other antimicrobial drug classes often
have limitations in treating infections due to
resistant Gram-positive bacteria. The fluoroqui-
nolones have limited activity against many Gram-
positive bacteria, especially for staphylococcal
species. Streptogramins are limited because of
poor tolerability and increasing resistance. Oxa-
zolidinones, a new class of antibiotics, are very
promising for treating resistant Gram-positive
infections; however, questions remain about their
tolerability and safety during long-term treat-
ment. Glycopeptides, including vancomycin and
teicoplanin, may have limited activity in ventila-
tor-associated pneumonia.
Cephalosporins have been available for over
three decades for the treatment of serious hospi-
tal-acquired infection, and cephalosporins often
account for the majority of antibiotic consumption
in the hospital. As a class, cephalosporins have
long been considered to have a broad spectrum of
activity. Thus, the key question is: can the sus-
ceptibility of S. aureus to b-lactam antibiotics be
restored?
While addressing this question, I recalled
the 150th birthday of Paul Ehrlich from a letter,
which was actually published in the Lancet in
1998. The letter addressed Ehrlich’s ‘Ingredients
for Success’: ‘Geld’, which is money; ‘Geduld’,
which is patience; ‘Geschick’, which is cleverness;
and ‘Glu¨ck’, which is luck. An additional factor is
health. Considering Ehrlich’s ‘Ingredients for
Success’, some progress may be expected in
identifying new antibiotics for treating MRSA.
In this publication, Dr Peter Appelbaum from
the USA will discuss the changing patterns of
MRSA resistance and the in-vitro microbiology
and spectrum of activity of ceftobiprole. Dr David
Livermore from the UK will discuss the use of
b-lactam antibiotics against MRSA and the use of
bacteriostatic vs. bactericidal agents for treating
Gram-positive infections.
One such agent is ceftobiprole, a broad-spec-
trum, novel cephalosporin with antimicrobial
activity against MRSA. Ceftobiprole has an inno-
vative structure whereby it is administered as a
prodrug, ceftobiprole medocaril, which is metab-
olised to the active drug ceftobiprole (Fig. 1).
Ceftobiprole is bactericidal and overcomes
transpeptidase-based b-lactam resistance in sta-
phylococci and pneumococci. Ceftobiprole also
exhibits favourable pharmacokinetic properties
and low protein binding in human serum,
and thus has the potential for use as first-line
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empirical therapy, especially in the surgical
intensive care unit.
Dr Henry Chambers from the USA will review
in-vivo and phase I data on ceftobiprole. An early
phase II study on ceftobiprole was conducted in
40 patients with complicated skin and skin struc-
ture infections (Heep M, Querner S, Harsch M,
O’Riordan W. Ceftobiprole [BAL 5788], the first
of a new class of anti-MRSA cephalosporins:
microbiological results from a phase II study in
complicated skin and skin structure infections.
44th ICAAC 2004, abstract L-361). Patients
received intravenous ceftobiprole 750 mg twice-
daily. Sites of infection included wounds, absces-
ses and cellulitis. In a modified intention-to-treat
analysis, 28 patients with infections caused by
methicillin-susceptible S. aureus, MRSA, strepto-
coccal species, coagulase-negative staphylococci
and Citrobacter freundii were microbiologically
evaluable. Most of the pathogens were eradicated
by ceftobiprole or were presumed to be eradi-
cated, and only two cases resulted in a clinical
cure with persistent colonisation. These results
provide evidence of the antimicrobial effective-
ness of ceftobiprole and support data from
in-vitro and animal studies with ceftobiprole. In
addition, the safety and tolerability profile was as
expected from a drug of the cephalosporin class.
Based on this unique profile of a broad-spec-
trum cephalosporin with potent activity against
MRSA, the FDA granted fast-track approval
status to ceftobiprole for the treatment of compli-
cated skin and skin structure infections and
nosocomial pneumonia. Phase III studies with
ceftobiprole for nosocomial pneumonia and
complicated skin and skin structure infections
are underway, and the results are eagerly
awaited.
Fig. 1. Chemical structure of ceftobiprole (top) and its
prodrug ceftobiprole medocaril (bottom).
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